Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
Gilead agreed to acquire worldwide rights to PepStar’s oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion cash payable at closing. HCXT-2001 is a Phase 1 oral macrocyclic peptide with an extended half-life. Closing was expected in the fourth quarter of 2026, subject to conditions; the candidate’s safety and efficacy remain unestablished.
An engineered nanoparticle delivered mRNAs encoding IL-1 receptor antagonist and an angiopoietin-like 3 derivative through intra-articular injection. The combination addressed inflammation and cartilage degeneration in several mouse arthritis models, with transcriptomic analyses supporting complementary biological effects. These findings broaden local mRNA therapy beyond vaccination, but durable structural benefit, repeated-dose safety, and effectiveness in human joints remain unproven.
Researchers characterized eight sotorasib solvates, including three previously unreported forms, using single-crystal diffraction and complementary thermal methods. Despite substantial structural similarities among most solvates, solvent removal led to different anhydrous-polymorph pathways. Experiments and molecular simulations point to local packing environments and thermal history as important factors, showing that similar solvates need not behave identically during drying.
A Crystal Growth & Design study combines CSP, force-field and lattice-dynamics calculations, machine-learning energy corrections, and scaled partition functions to model mixed crystals of anthracene, acridine, and phenazine. It reproduces key experimental binary trends and a ternary phase while predicting additional stable compositions. The validation uses model molecular systems rather than pharmaceutical drug products.
Biomay introduced a personalized cancer-vaccine manufacturing service, reporting an approximately three-week mRNA workflow from starting material through quality release. The process covers template DNA, transcription, LNP manufacturing, testing, and qualified-person release, supported by in-house analytics and dedicated suites. Biomay cited experience releasing more than 120 personalized GMP batches. Timelines and capacity claims are supplier-reported and require program-specific confirmation.
BioNTech inaugurated its clinical-scale mRNA manufacturing and R&D facility at La Trobe University’s Bundoora campus in Melbourne. Built around modular BioNTainer technology, the site combines drug-substance production, formulation, and aseptic filling, with subsidized access planned for researchers and start-ups. GMP operational readiness is expected in mid-to-late 2027 after successful commissioning; inauguration does not mean GMP operations have already begun.
A minireview distinguishes bulk encapsulation efficiency from particle occupancy and RNA copy-number distributions. High encapsulation efficiency can coexist with RNA-negative particles, and process changes may alter loading without changing average size. The author cautions that eliminating empty particles does not necessarily improve activity; product-specific evidence must establish whether occupancy is a critical quality attribute.
Acuitas summarized World Vaccine Congress Europe data showing enhanced mRNA vaccine immune responses with ALC-315 in animal tumor models, alongside improved potency of newer lipids in an influenza vaccine model. The release describes preclinical tumor, survival, and immune-response findings. These results should not be read as demonstrated clinical efficacy or a human safety advantage.
Researchers combined terahertz spectroscopy, Born–Oppenheimer molecular dynamics, and interpretable deep learning to monitor salt formation in an 8-hydroxyquinolinium salicylate model system. Measurements across 80–300 K helped assign lattice-vibration features and establish a stage-resolved analytical workflow. The study is a model-system demonstration of process monitoring, rather than evidence of deployment across commercial active pharmaceutical ingredient processes.
Cosette announced FDA approval of EVOXAC cevimeline hydrochloride oral solution for dry-mouth symptoms in adults with Sjögren’s disease. The liquid formulation offers an alternative for patients who have difficulty swallowing capsules. Developed internally, it used an application pathway relying partly on existing capsule safety and efficacy data, with U.S. commercial availability expected by the end of 2026.
A mouse study compared LNP-delivered self-amplifying RNA and an Ad5 vaccine encoding the same RSV prefusion F antigen. Intramuscular dosing produced distinct immune patterns: saRNA favored pulmonary mucosal and tissue-resident memory responses, while Ad5 generated stronger systemic responses. The comparison concerns immune architecture, not demonstrated superiority in human protection.
Ascletis reported that ASC36o, an oral amylin receptor agonist tablet, had an approximately seven-day half-life and 6%–8% oral bioavailability in nonhuman primates. The company said a US Phase 1 study was underway, with human PK results expected by year-end 2026. The quantitative findings are preclinical and do not yet establish once-weekly oral dosing in humans.
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.